Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2022; 13(8): 688-701
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.688
Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant
Ajacio Bandeira de Mello Brandão, Santiago Rodriguez, Claudio Augusto Marroni, Matheus V Fernandes, Gabriela Perdomo Coral, Graduate Program in Medicine: Hepatology, School of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050170, RS, Brazil
Ajacio Bandeira de Mello Brandão, Alfeu de Medeiros Fleck Jr, Claudio Augusto Marroni, Liver Transplantation Group, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre 90020090, RS, Brazil
Santiago Rodriguez, Department of Hepatology, Hospital Vozandes Quito-HVQ, Quito 170521, Ecuador
Mário B Wagner, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90035002, RS, Brazil
Alex Hörbe, Interventional Radiology Unit, Santa Casa de Misericórdia de, Porto Alegre 90020090, RS, Brazil
Carlos TS Cerski, Department of Pathology, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035002, RS, Brazil
Author contributions: All the authors solely contributed to this paper.
Institutional review board statement: The Institutional Review Board of Santa Casa de Misericórdia de Porto Alegre approved the study protocol (No. 4.250.889).
Informed consent statement: Informed consent was waived due to the non-interventional design of the study and retrospective nature of data collection. All investigators signed a data use agreement to ensure the ethical and secure use of the data.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement checklist of items, and the manuscript was prepared and revised according to the STROBE Statement checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ajacio Bandeira de Mello Brandão, PhD, Academic Research, Graduate Program in Medicine: Hepatology, School of Medicine, Universidade Federal de Ciências da Saúde de Porto Alegre, R. Eng. Álvaro Nunes Pereira, 400/402, Porto Alegre 90050170, RS, Brazil. ajaciob@gmail.com
Received: April 8, 2022
Peer-review started: April 8, 2022
First decision: May 12, 2022
Revised: June 14, 2022
Accepted: July 11, 2022
Article in press: July 11, 2022
Published online: August 24, 2022
Processing time: 136 Days and 17.1 Hours
Peer-review started: April 8, 2022
First decision: May 12, 2022
Revised: June 14, 2022
Accepted: July 11, 2022
Article in press: July 11, 2022
Published online: August 24, 2022
Processing time: 136 Days and 17.1 Hours
Core Tip
Core Tip: This retrospective cohort study analyzes the outcomes of patients undergoing liver trans-plantation (LT) with a presumptive diagnosis of hepatocellular carcinoma (HCC) in which explant analysis identified that they actually had intrahepatic cholangiocarcinoma (ICC) or mixed hepatocellular cholangiocarcinoma (HCC-CC). Propensity score matching was used to analyze tumor recurrence, overall mortality, and recurrence-free survival in LT recipients with pathologically confirmed ICC or HCC-CC matched 1:8 to those with HCC. Patients with ICC have worse outcomes than patients undergoing LT for HCC, even when matched for explant pathology. Outcomes did not differ significantly between patients with HCC-CC and patients with HCC.